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Here we present the complete genomic sequence of bovine herpesvirus 5 (BHV-5), an alphaherpesvirus re-
sponsible for fatal meningoencephalitis in cattle. The 138,390-bp genome encodes 70 putative proteins and re-
sembles the 2 subgroup of herpesviruses in genomic organization and gene content. BHV-5 is very similar to
BHV-1, the etiological agent of infectious bovine rhinotracheitis, as reflected by the high level of amino acid identity
in their protein repertoires (average, 82%). The highest similarity to BHV-1 products (>95% amino acid iden-
tity) is found in proteins involved in viral DNA replication and processing (UL5, UL15, UL29, and UL39) and
in virion proteins (UL14, UL19, UL48, and US6). Among the least conserved (<75%) are the homologues of
immediate-early (IE) proteins BICP0, BICP4, and BICP22, the three proteins being longer in BHV-5 than in
BHV-1. The structure of the BHV-5 latency-related (LR) region departs markedly from that of BHV-1 in both
coding and transcriptional regulatory regions. Given the potential significance of IE genes and the LR region
in virus-neuron interactions, it is likely these differences contribute to BHV-5 neuropathogenicity.
Bovine herpesvirus 5 (BHV-5) is a pathogen of cattle re-
sponsible for sporadic epizootics of fatal meningoencephalitis
(6, 37). Due to similarities in virion morphology, cytopathic
effects in cell culture, and antigenic properties (37, 38), BHV-5
was formerly regarded as a neuropathogenic variant of bovine
herpesvirus 1 (BHV-1), the etiological agent of infectious bo-
vine rhinotracheitis and vulvovaginitis. Subsequent compara-
tive studies based on restriction site mapping of viral DNA (28,
32, 93), cross-neutralization tests, and monoclonal antibody
reactivity (24, 63) indicated that the viruses differ in genomic
and antigenic properties. In 1992 BHV-5 was recognized as a
distinct virus by the International Committee on Taxonomy of
Viruses (78).
Both BHV-5 and BHV-1 are neurotropic viruses, but only
BHV-5 is capable of significant replication in the central ner-
vous system (CNS) and induction of neurological disease (5,
10). Outbreaks of meningoencephalitis caused by BHV-5 have
been reported in Australia (37), North and South America (8,
15, 42, 77), and Europe (9, 66). The course of the disease after
experimental infection with BHV-5 depends on the virus iso-
late, the route of inoculation, and the immunological status
and age of the animal. Calves up to 4 months of age are most
susceptible. During the first week following intranasal inocu-
lation of virus, the animals either present signs of mild rhinitis
and conjunctivitis or they remain asymptomatic (5, 16, 66, 73).
At this point, animals can recover from infection or, alterna-
tively, progress to neurological disease and die. Regardless of
the appearance of clinical neurological disease in infected
calves, BHV-5 invades the CNS and causes various degrees of
pathology (16, 65). The neural route followed by BHV-5 to
invade the CNS in cattle has not been defined, although both
the trigeminal and the olfactory pathways have been impli-
cated (6, 65). In a rabbit model for BHV-5, the olfactory
pathway is the main route for neural dissemination (19, 57).
At times when no infectious virus can be isolated from pe-
ripheral sites, surviving animals exhibit BHV-5 viral sequences
in their trigeminal ganglia (TG), indicating that, as in BHV-1,
BHV-5 remains latent in the TG (5, 16, 65, 91). Latent virus
can be reactivated after treatment of latently infected animals
with dexamethasone (10, 16). Although recrudescence of clin-
ical disease has been observed after experimental virus reacti-
vation, its occurrence in nature remains unknown (73). Previ-
ous vaccination of cattle against BHV-1 resulted in protection
against BHV-5-induced neuropathology and clinical signs of
disease (16). This is partially explained by the cross-reactivity
of induced BHV-1 neutralizing antibodies (24). Vaccination
with BHV-1, however, does not prevent establishment of la-
tency by BHV-5 (16).
The marked neuroinvasiveness (and often neurovirulence)
displayed by BHV-5 contrasts with the inability of BHV-1 to
invade the CNS and cause neurological disease to any signifi-
cant degree. During infection with other neurotropic herpes-
viruses (e.g., pseudorabies virus [PRV] and herpes simplex
virus [HSV]), neuroinvasiveness and local virus spread in the
CNS are properties which largely rely on certain viral envelope
glycoproteins (46, 67). However, other viral functions could
contribute to a successful infection of the CNS.
Comparative genomics has proven useful in identifying genes
involved in virulence. The complete BHV-1 genomic sequence,
a composite including sequences of five different virus strains,
is available (GenBank accession number AJ004801). However,
less than 15% of the BHV-5 genome (mostly representing
envelope glycoproteins) has been sequenced (1, 18, 20, 22, 31,
40, 64, 80, 86). Here we present the complete sequence of a
neurovirulent strain of BHV-5, with analysis and comparison
to BHV-1.
* Corresponding author. Mailing address: Plum Island Animal Dis-
ease Center, P.O. Box 848, Greenport, NY 11944-0848. Phone: (631)
323-3330. Fax: (631) 323-3044. E-mail: drock@cshore.com.
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MATERIALS AND METHODS
DNA isolation, cloning, and sequencing. BHV-5 strain SV507/99 was originally
isolated from bovine brain tissue from a case of fatal encephalitis in southern
Brazil (91).
To obtain viral DNA, BHV-5-infected MDBK cells were pelleted, washed in
NTE buffer (10 mM Tris [pH 8.0], 150 mM NaCl, 5 mM EDTA), resuspended
in KTE buffer (10 mM Tris [pH 8.0], 10 mM KCl, 5 mM EDTA), and incubated
in KTE buffer containing 0.25% -mercaptoethanol and 10% Triton X-100 for
10 min on ice. After centrifugation at 3,000 rpm (Sorvall), 5 min, 4°C, virus in the
supernatant was pelleted onto a 30% sucrose cushion (13,000 rpm, 1 h, 4°C),
resuspended in Tris-EDTA (TE; pH 8.0), incubated in the presence of sodium
dodecyl sulfate (0.5% [wt/vol]) and proteinase K (10 mg/ml) for 2 h at 37°C, and
phenol extracted. Viral DNA was precipitated with ethanol and resuspended in
TE buffer (pH 8.0). Random 1- to 8-kbp DNA fragments were obtained by
incomplete enzymatic digestion with AciI endonuclease (New England Biolabs,
Beverly, Mass.). DNA fragments of 1.5 to 3 kbp were isolated after separation in
size exclusion columns (Clontech), cloned into the dephosphorylated AciI site of
pUC19 plasmids, and grown in Escherichia coli DH10B cells (Gibco BRL, Gaith-
ersburg, Md.). Plasmids were purified by alkaline lysis as instructed by the
manufacturer (Eppendorf 5 Prime; Boulder, Colo.). DNA templates were
sequenced from both ends with M13 forward and reverse primers and from
selected plasmids with transposon insertion (EZ::TNKAN-2 transposon in-
sertion kit; Epicentre Tech., Madison, Wis.), using dideoxy-chain terminator
sequencing chemistries (82) and an Applied Biosystems PRISM 3700 automated
DNA sequencer (PE Biosystems, Foster City, Calif.). Bases were called from
chromatogram traces with Phred (35), which also produced a quality file con-
taining a predicted probability error at each base position.
DNA sequence analysis. DNA sequences were assembled with Phrap (34),
using the quality files and default settings to produce a consensus sequence which
was manually edited with Consed (41). An identical sequence was assembled
using the Cap3 assembler with quality files and clone length constraints (45). The
final DNA consensus sequence represented an average eightfold redundancy at
each base position. Gap closure was achieved by primer walking of gap-spanning
clones and sequencing of PCR products. A total of 7,835 usable traces were
assembled into a 127,162-bp contig by bidirectional sequencing of random clones
and 61 PCR products, including those that crossed the terminal junction se-
quences from concatemeric replicative intermediates. The assembled contig had
an estimated error rate of 0.03/10 kbp and showed no evidence of polymor-
phism using Polyphred analysis (34), including within the single, complete unique
short (US) repeat sequence which assembled with double average redundancy at
each base position, consistent with a bimolar representation of repeat sequences
derived from two identical copies, as found in other alphaherpesviruses. Thus,
the assembled contig contained 570 bp of the terminal repeat (TR) at the left
terminus, all of the unique long (UL), internal repeat (IR), and US sequences,
and 738 bp of the TR at the right terminus. IR and TR sequences were also
assembled separately with clones containing the unique-repeat junctions and
overlapping clones, using length constraints and position as provided by the
computer assembly programs. These assemblies were manually joined at the
unique-repeat boundaries, thus providing the complete genome. For descriptive
purposes, we have presented BHV-5 in a linearized fashion as described by
Dolan et al. (29). Genome DNA composition, structure, repeats, and restriction
enzyme patterns were analyzed as previously described (2). Open reading frames
(ORFs) encoding proteins of 60 amino acids with a methionine start codon
(88) were evaluated for coding potential using the Hexamer (ftp.sanger.ac.uk/
pub/rd) and Glimmer (81) computer programs. Other criteria included similarity
to other herpesvirus and compact gene arrangements with little gene overlap.
Homology searches were conducted using BLAST (3), PSIBLAST (4), FASTA
(72), BLIMPS (92), and HMMER (87) programs with the Prosite, Pfam, Pro-
dom, Sbase, Blocks, Domo, and GenBank databases (14). GCG (26), MEMSAT
(54), and SAPS (12) programs were used for gene analysis. The coding potential
and splicing patterns in the latency-related (LR) region of BHV-5 and BHV-1
were analyzed with Glimmer, Hexamer, Splice (a neural network program for
eukaryotic splice site prediction; ftp://genome.lbl.gov/pub/reese/SPLICE), NNPP
(eukaryotic promoter prediction; ftp://genome.lbl.gov/pub/reese/NNPP), TIGR
GeneSplicer (74), HMM gene trained on human and Drosophila gene sets (55),
and Eponine for transcription start site detection (30). We also compared
BHV-1 mapping data to the BHV-5 LR region.
Nucleotide sequence accession number. The BHV-5 genome sequence has
been deposited in GenBank under accession no. AY261359.
RESULTS AND DISCUSSION
Genome organization. The BHV-5 genome is 138,390 bp
long, 2,518 bp longer than the BHV-1 genome, and contains a
75% GC base composition. The genome consists of two
unique sequences, long or UL (104,054 bp) and short or US
(9,548 bp), with the latter being flanked by inverted IR and TR
elements of 12,109 bp each. This arrangement corresponds to
the D-type herpesviral genome (62).
The BHV-5 origins of DNA replication (ORI) are located in
the repeat regions from nucleotide positions 113206 to 113418
and 129595 to 129807. ORI sequences consist of two imperfect
AT-rich direct repeats (ORIa and ORIb) which contain her-
pesvirus consensus sites for the origin-binding protein (84). As
in BHV-1, an additional truncated repeat (ORIc) is located
130 bp downstream from ORIb.
Gene characterization. BHV-5 contains 72 genes (Table 1),
of which 68 are present as single copies within the unique
regions and 2 initiate and are completely located within the
repeat regions (BICP4 and BICP22). BHV-5 proteins are most
similar to homologues from BHV-1, averaging 82% amino acid
identity. All BHV-5 ORFs are present in BHV-1; however,
BHV-5 lacks a homologue of UL0.5. Among nonbovine her-
pesviruses, ORFs of equine herpesviruses (EHV) 1 and 4 are
the most similar to those of BHV-5 (28 to 69% amino acid
identity). The similarity in gene arrangement and the high
percentage of amino acid identity between BHV-5 and previ-
ously sequenced alphaherpesviruses support the inclusion of
BHV-5 in the 2 subgroup of herpesviruses (62), as was pre-
viously suggested by envelope glycoprotein B sequence analysis
(80).
UL region. The UL region, extending from nucleotide posi-
tions 570 to 104623, contains 60 putative genes. Starting from
the left end of the genome, the first 58 genes are colinear with
their BHV-1 counterparts and represent 73% of the BHV-5
genome. Similarly, the first 53 BHV-5 genes (with the excep-
tion of circ) are largely colinear with genes UL54 to UL4 of
HSV type 1 (HSV-1). Predicted UL proteins average 84%
amino acid identity to BHV-1 homologues, with the most sim-
ilar (95% amino acid identity) involving viral DNA replica-
tion and processing (UL5, UL15, UL29, and UL39), tegument
(UL14 and UL48), and capsid (UL19). Compared with non-
bovine herpesviruses, all BHV-5 capsid proteins and six of
eight proteins involved in viral DNA replication or processing
are the most conserved (60%).
BHV-5 UL49, UL44, UL24, UL11, UL3.5, UL3, UL0.7, LR,
and BICP0 are the least conserved UL genes (75%) relative
to BHV-1 and are discussed below. Homologues of UL49 and
UL3 in HSV-1 and of UL49 in BHV-1 are not essential for
virus growth in cultured cells, suggesting a role for these genes
in viral pathogenesis and host range (7, 59, 75).
BHV-5 UL44 encodes glycoprotein C (gC), which is not
essential for neurovirulence in strain TX89; however, it affects
neurotropism and is important for high levels of virus replica-
tion and full expression of virulence in the rabbit CNS (21). As
alphaherpesvirus gC mediates primary attachment of virus to
target cells via binding to surface glycans, variability in the
heparin binding sites of BHV-5 gC (gC5) and BHV-1 gC (gC1)
likely account for differences in their heparin-binding pheno-
types (60). Although gC5 and gC1 are 75% identical, the ami-
10340 DELHON ET AL. J. VIROL.
 
TABLE 1. Characterization of BHV-5 genes
ORF
no.
ORF
name
Position
(nt)a
Length
(aa)a
BHV-5
accession
no.b
BHV-1 Closest non-BHV-1 species
Predicted product and/or functiondLength
(aa)
%
Identity
Accession
no.b Name
c Length
(aa)
%
Identity
Accession
no.b
BHV5-01 circ 1167–1901 245 247 84 M96453 EHV-1 257 43 P28988 Myristylated virion protein
BHV5-02 UL54 3482–2274 403 400 82 M96453 EHV-1 470 47 Q05906 Regulates and transports RNA
BHV5-03 UL53 4699–3707 331 332 85 U34593 EHV-1 343 39 AF030027 Glycoprotein K
BHV5-04 UL52 7931–4677 1,085 1,074 83 Z54206 EHV-1 1,081 44 P28962 Component of DNA helicase-primase complex
BHV5-05 UL51 7930–8715 262 243 81 Z54206 PRV 236 49 X87246 Palmitoylated protein (cytoplasm)
BHV5-06 UL50 9821–8859 321 325 83 S62816 EHV-1 326 40 P28892 Deoxyuridine triphosphatase (dUTPase)
BHV5-07 UL49.5 9772–10056 95 96 81 S62816 PRV 98 36 U38547 Glycoprotein N
BHV5-08 UL49 10193–10993 267 258 72 U211137 EHV-1 304 41 X17684 Tegument protein
BHV5-09 UL48 11189–12634 482 AY034598 505 98 Z11610 EHV-4 448 52 AF030027 trans-Inducing factor (tegument)
BHV5-10 UL47 12808–15030 741 739 93 P36338 EHV-4 871 35 P28929 Tegument phosphoprotein
BHV5-11 UL46 15166–17367 734 748 82 Z54206 EHV-1 747 40 P28937 Tegument protein
BHV5-12 UL44 19051–17594 486 Z49224 508 75 Z54206 CaHV-1 521 59 Z49225 Glycoprotein C
BHV5-13 UL43 20382–19243 380 378 88 Z54206 EHV-4 403 28 AF030027 Virion protein (membrane)
BHV5-14 UL42 21671–20436 412 408 79 Z54206 PRV 384 38 P36702 Processivity factor for DNA polymerase
BHV5-15 UL41 21714–23288 525 459 91 Z54206 EHV-1 497 48 P28957 Virion host shutoff factor (tegument)
BHV5-16 UL40 24363–23419 315 314 91 Q01319 PRV 303 76 X72087 Ribonucleotide reductase small subunit
BHV5-17 UL39 26785–24386 800 787 97 Z54206 PRV 835 67 X72087 Ribonucleotide reductase large subunit
BHV5-18 UL38 28787–27153 545 474 87 Z54206 EHV-4 462 47 AF030027 Capsid protein
BHV5-19 UL37 28869–32030 1,078 1,024 88 Z54206 EHV-4 1,021 41 AF030027 Tegument protein
BHV5-20 UL36 32133–41744 3,204 3,247 80 Z78205 EHV-1 3,421 40 P28955 Very large tegument protein
BHV5-21 UL35 42351–41977 125 124 87 Z78205 PRV 103 54 AJ276165 Capsid protein
BHV5-22 UL34 43226–42399 276 260 83 Z78205 PRV 260 58 AF301599 Virion protein (membrane)
BHV5-23 UL33 43639–43310 110 108 89 Z78205 EHV-1 162 59 P28953 Capsid packaging protein
BHV5-24 UL32 43620–45413 598 601 89 Z78205 EHV-1 620 53 P28952 Cleavage and packaging protein
BHV5-25 UL31 45409–46545 379 361 84 Z78205 EHV-4 326 64 AF030027 UL34-associated nuclear protein
BHV5-26 UL30 50224–46475 1,250 1,246 90 X94677 EHV-1 1,220 61 P28858 DNA polymerase, catalytic subunit
BHV5-27 UL29 50495–54118 1,208 1,203 95 X94677 EHV-1 1,209 62 P28932 Single-stranded DNA binding protein
BHV5-28 UL28 54358–56805 816 826 90 X94677 EHV-1 775 55 M86664 Cleavage and packaging protein
BHV5-29 UL27 56661–59501 947 AF359759 932 93 P12640 FHV-1 948 58 S49775 Glycoprotein B
BHV5-30 UL26.5 60960–60016 315 308 80 431809 HSV-2 329 38 L37443 Capsid scaffolding protein
BHV5-31 UL26 61872–60016 619 621 83 U31809 EHV-1 646 46 P28936 Capsid maturation serine protease
BHV5-32 UL25 63788–61980 603 598 94 AJ004801 EHV-1 587 58 P28928 DNA packaging virion protein
BHV5-33 UL24 64609–63773 279 293 74 L39072 EHV-1 272 45 P28927 Putative membrane-associated protein
BHV5-34 UL23 64608–65675 356 S56149 359 83 P36226 EHV-4 352 46 AF030027 Thymidine kinase
BHV5-35 UL22 65795–68338 848 AF113752 842 86 P27599 EHV-4 855 33 A21045 Glycoprotein H
BHV5-36 UL21 70346–68538 603 574 77 Z48053 EHV-1 530 38 P28972 Tegument protein
BHV5-37 UL20 70386–71144 253 231 93 Z48053 EHV-1 239 35 P28971 Virion protein (membrane)
BHV5-38 UL19 71227–75399 1,391 1,385 97 Z48053 EHV-1 1,376 69 P28920 Major capsid protein
BHV5-39 UL18 75509–76456 316 316 92 Z48053 EHV-1 314 60 P28921 Capsid protein
BHV5-40 UL17 77927–80047 707 701 90 Z48053 EHV-1 706 44 P28950 Tegument protein
BHV5-41 UL16 80077–81105 343 339 93 Z48053 EHV-1 370 47 P28970 Virion protein
BHV5-42 UL15 82277–76670 737 735 95 Z48053 EHV-1 734 63 P28969 DNA cleavage-packaging protein (terminase)
BHV5-43 UL14 82340–83011 224 222 97 Z48053 EHV-4 321 48 AF030027 Minor tegument protein
BHV5-44 UL13 82923–84407 495 492 90 Z48053 EHV-1 594 38 P28966 Virion serine/threonine protein kinase
BHV5-45 UL12 84407–85867 487 487 88 Z48053 PRV 483 51 X97257 Alkaline exonuclease
BHV5-46 UL11 85822–86121 100 89 73 Z48053 EHV-4 75 48 AF030027 Myristylated protein (tegument)
BHV5-47 UL10 87526–86270 419 438 85 AJ004801 EHV-1 450 38 P28948 Glycoprotein M
BHV5-48 UL9 87647–90115 823 859 89 Z48053 EHV-4 887 57 AF030027 Ori-binding protein
BHV5-49 UL8 90216–92486 757 748 89 AJ004801 EHV-4 751 40 AF030027 Component of DNA helicase-primase complex
BHV5-50 UL7 93451–92549 301 299 88 X91751 EHV-1 303 40 P28945 Virion-associated protein
BHV5-51 UL6 95795–93336 820 688 84 Z48053 PRV 643 62 X97257 Virion protein
BHV5-52 UL5 95551–98064 838 838 99 Z48053 EHV-1 861 64 P28934 Component of DNA helicase-primase complex
BHV5-53 UL4 98088–98651 188 185 86 Z48053 EHV-4 227 39 AF030027 Nuclear protein
BHV5-54 UL3.5 99127–98684 148 126 69 U32173 EHV-4 133 29 AF030027 Virion protein
BHV5-55 UL3 99786–99136 217 204 75 U32173 EHV-1 212 53 P28942 Phosphoprotein
BHV5-56 UL2 100729–99836 298 301 76 AJ004801 PRV 339 58 L13855 Uracil-DNA glycosylase
BHV5-57 UL1 101201–100716 162 158 81 AJ004801 FHV-1 147 39 AF022391 Glycoprotein L
BHV5-58 UL0.7 101005–101607 201 97 41 AJ004801 HHV-6b 1,520 31 AF157706 Unknown
UL0.5 Not present 87 AJ004801 Unknown
BHV5-59a LRORF2 102159–102311 51e 181 82 M61143 LR region
BHV5-59b LRORF1 102553–103632 360 336 66 M61143 LR region
BHV5-60 BICP0 104408–102249 720 676 70 P29836 PRV 410 32 A40505 IE transactivator protein with Zn finger
BHV5-61 BICP4 109909–105686 1,406 1,343 75 L14320 EHV-1 1,487 42 P17473 Positive and negative gene regulator
BHV5-62 BICP22 114776–115717 314 300 68 X76943 EHV-1 278 40 Z67986 Transcription factor
BHV5-63 US1.67 117249–116509 247 243 79 AJ004801 EHV-1 272 35 P28984 Virion protein (EHV-1)
BHV5-64 US2 117987–117310 226 220 69 AJ004801 EHV-1 303 37 P32517 Tegument protein
BHV5-65 US3 118110–119441 444 468 79 AJ004801 EHV-4 384 42 AF030027 Virion serine/threonine protein kinase
BHV5-66 US4 119552–120871 440 X99755 444 72 AJ004801 FHV-1 435 32 S72415 Glycoprotein G
BHV5-67 US6 121129–122379 417 U14656 417 98 A25177 CeHV-1 179 84 AF078735 Glycoprotein D
BHV5-68 US7 122532–123692 387 382 78 AJ004801 EHV-1 424 30 P18553 Glycoprotein I
BHV5-69 US8 123984–125780 597 AF208294 575 74 AJ004801 EHV-1 552 41 P24380 Glycoprotein E
BHV5-70 US9 125875–126276 134 AY064172 144 79 Z23068 PRV 106 48 U27487 Virion protein (tegument)
BHV5-71 BICP22 128237–127296 314 300 67 X76943 EHV-1 272 40 Z67986 Transcription factor
BHV5-72 BICP4 133104–137327 1,406 1,343 75 L14320 EHV-1 1,487 42 P17473 Positive and negative gene regulator
a aa, amino acids; nt, nucleotides.
b Accession numbers are from GenBank or SwissProtein.
c Names for viruses: EHV-1, equine herpesvirus 1; PRV, pseudorabies virus; EHV-4, equine herpesvirus 4; CaHV-1, caprine herpesvirus 1; HSV-2, herpes simplex
virus type 2; FHV-1, feline herpesvirus 1; HHV-6b, human herpesvirus 6B; CeHV-1, cervid herpesvirus 1.
d Function was deduced from the degree of amino acid similarity to products of known genes.
e The remaining homologous region is present but contains an in-frame stop and two in-frame frameshifts.
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no-terminal third of the proteins (amino acids 1 to 102 and 1 to
123, respectively) differ significantly. Notably, there is a 35-
amino-acid deletion in gC5 which removes two potential N-
linked glycosylation sites present in gC1 (amino acids 93 and
111) (36) and a gC1-specific epitope (amino acids 103 to 122)
(18). Comparison of gC sequences between strain SV507/99
(this report) and strain TX89 (18) reveals substantial differ-
ences at the amino-terminal third. However, a more detailed
analysis shows that the proteins are 97% identical and that the
discrepancy likely results from a missing base at position 480 in
the published TX89 sequence.
The homologue of UL24 in HSV-1 is required for efficient
replication in TG of mice (50). The homologue of UL11 in
HSV-1 encodes a tegument protein with roles in virion envel-
opment and egress (7). BHV-5 and BHV-1 UL3.5 and UL0.7
are not found in other herpesviruses, and their functions re-
main unknown. BHV-5 lacks a homologue of BHV-1 UL0.5,
which is predicted to encode an 87-amino-acid protein of un-
known function.
The latency-related (LR) gene is postulated to contribute via
alternative splicing to the LR protein(s) (27, 44), whereas
BICP0 encodes a homologue of BHV-1 BICP0, an immediate-
early (IE) and early (E) transactivator (95). Given the poten-
tial roles of LR and BICP0 genes in virulence and host range,
these genes are treated in more detail below (see “IE genes”
and “The LR region,” below).
US region. The US region, extending from positions 116733
to 126280, contains eight genes (US1.67, 2 to 4, and 6 to 9),
four of which have been previously sequenced (1, 20, 22, 31).
BHV-5 US genes exhibit 69 to 98% amino acid identity (aver-
age, 79%) and overall less conservation to BHV-1 homologues
than those within the UL region (84% average amino acid
identity) (58). BHV-5 US2 to US9 are syntenic with homo-
logues in HSV-1, with the exception of the US5 homologue,
which is lacking in BHV-5.
The two BHV-5 genes located at the ends of the US are
likely significant for virus-host interactions. The gene at the
US-IR boundary, US1.67, contains the 75 carboxy-terminal
amino acids within the IR and is homologous to ORFs found
in other members of the 2 herpesvirus subgroup. Notably, the
homologue of US1.67 in EHV-1 is a virulence determinant and
is involved in egress of viral nucleocapsids (70, 71, 89). The
gene at the US-TR boundary, US9, is essential for neuroviru-
lence in the TX89 strain. Following intranasal inoculation of
rabbits, a TX89 strain US9 deletion mutant failed to invade the
CNS mainly due to an inability of the virus to spread to the
olfactory bulb via anterograde transport (22).
BHV-5 US2, US4, and US8 are the least-conserved US
ORFs (75%) in comparison with BHV-1. The US2 homo-
logue in HSV-1 and HSV-2 seems dispensable in tissue culture
and is not involved in HSV-2 neuropathogenesis in mice (52,
61). BHV-5 US4 encodes a glycosaminoglycan-associated pro-
tein (31) and is 72% identical to BHV-1 gG, which is involved
in cell-cell virus transmission in vitro (69) and in prevention of
apoptosis in certain cell lines (68). BHV-5 US8 encodes gE,
which is important for neurovirulence in rabbits. Deletion of
BHV-5 US8 or its substitution by BHV-1 gE resulted in viruses
that replicated and spread much less efficiently in the rabbit
brain than revertant or wild-type viruses (20).
Repeats. The IR and TR regions, located at nucleotide po-
sitions 104624 to 116732 and 126281 to 138389, respectively,
are 12,109 bp in length. Each repeat contains two genes,
BICP4 and BICP22, which are 75 and 68% identical to BHV-1
BICP4 and BICP22, respectively (see “IE genes,” below).
Among nonbovine herpesviruses, genes of EHV-1 are the most
similar to BICP4 (42% amino acid identity) and BICP22 (40%
amino acid identity). Interestingly, a homologue of the 1 34.5
gene, a neurovirulence determinant of HSV-1, is not present in
BHV-5 (79).
A 4,867-bp noncoding region separates BICP4 from BICP22
start codons. Overall, this region is 56% identical to the ho-
mologous BHV-1 intergenic region and contains transcrip-
tional regulatory elements for the flanking IE genes and the
origins of DNA replication.
IE genes. Herpesvirus IE genes are critical regulators of viral
gene expression. BHV-5 BICP0, BICP4, and BICP22, the ho-
mologues of BHV-1 IE genes BICP0, BICP4, and BICP22, are
relatively less conserved than other classes of viral genes (Ta-
ble 1).
In BHV-1, the BICP0 gene is transcribed at IE and E times
postinfection from two separate promoters, leading to accu-
mulation of 2.9- and 2.6-kb RNAs, respectively (94, 95). The
IE promoter also controls BICP4 expression at IE times
postinfection. A BICP0-specific transcript of similar size has
been detected in BHV-5-infected cells at IE times (96). Several
sequence elements involved in IE transcription and RNA pro-
cessing of BHV-1 BICP0, including the TATA box (BHV-5 po-
sition 110799), major transcription start site (position 110766),
donor and acceptor splice sites (positions 110417 and 104413,
respectively), and polyadenylation signal (position 102150), are
conserved in BHV-5. Further, potential TATA and SP1 sites
are located at 39 and 71 relative to the first BICP0 codon,
respectively, suggesting a similar promoter may direct E ex-
pression of BHV-5 BICP0 as in BHV-1 (95). Taken together,
these features suggest that common mechanisms control
BICP0 transcription in the two viruses.
BHV-5 BICP0 shares 70% amino acid identity with BHV-1
BICP0. Most amino acid differences are found at the carboxy
half of the protein, a region which plays a role in subcellular
localization of ICP0-like proteins (33, 47). BHV-5 BICP0 is 44
amino acids longer that its BHV-1 counterpart, including sev-
eral small amino acid insertions and a 30-amino-acid extension
at the carboxy terminus. This difference is likely responsible for
the slightly larger size of IE transcripts originated from BHV-5
BICP0 relative to those from BHV-1 (96). Both BHV-5 and
BHV-1 BICP0s are most similar in the amino half, which
contains a conserved acidic cluster (amino acids 273 to 323 in
BHV-5) and a C3HC4 zinc ring finger (amino acids 22 to 59).
However, the region between amino acids 119 and 145 (110 to
155 in BHV-1) is poorly conserved and includes a 20-amino-
acid deletion in BHV-5. In BHV-1, the BICP0 ring finger has
been implicated in promoting transactivation, stimulation of
productive infection, and cytotoxicity (47). It is not known if
BHV-1 BICP0 contributes to virus pathogenesis; however, a
point mutation in HSV-1 ICP0 significantly reduced neuroin-
vasiveness of an HSV-1 neurovirulent strain after peripheral
inoculation of mice (90).
BHV-5 BICP4 encodes the homologue of BHV-1 BICP4, an
IE transactivator and transrepressor (84). Based on sequence
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homologies, alphaherpesvirus ICP4 orthologs are divided into
regions I to V from the amino to the carboxy terminus (13, 17,
43, 84). BHV-5 and BHV-1 ICP4 are most similar (90 to 100%
amino acid identity) within regions II and IV. When compared
with HSV-1, BHV-5 BICP4 regions II and IV are also the most
similar (50% amino acid identity). HSV-1 ICP4 region II is
involved in homodimerization and DNA binding, whereas re-
gion IV is required for efficient transactivation (see reference
13 and references therein). BHV-5 BICP4 is 63 amino acids
longer than BHV-1 BICP4, and this may be responsible for the
slightly larger size of IE transcripts originated from BHV-5
BICP4 relative to their BHV-1 counterparts (96). The differ-
ence in length is partially due to a 47-amino-acid insertion in
BHV-5 BICP4 region III, which includes a unique stretch of
the dipeptide DG between two glutamic acid-rich clusters
unique to bovine alphaherpesvirus ICP4s. BHV-5 BICP22 en-
codes the homologue of the BHV-1 IE and late transrepressor
BICP22 (85). Most differences are observed in the carboxy
halves of the proteins (48% amino acid identity versus 82% in
the amino termini). This region contains 30 serines in BHV-5
and 16 in BHV-1 in a tract of 35 residues.
The LR region. The BHV-1 LR region is the only transcrip-
tionally active region in latently infected neurons and is hy-
pothesized to play a role in latent infections (44, 76). In vitro,
the BHV-1 LR gene inhibits cell cycle progression (83),
BICP0-dependent activation of productive infection (39), and
apoptosis (23). Within the LR gene there exist two major
ORFs designated ORF1 and ORF2, where ORF1 is com-
pletely overlapped by BICP0 (56). Using an antibody against
the amino terminus of ORF2, an LR protein was detected in
lytically infected cells and in latently infected TG neurons (44,
51). Infection of cattle with mutant BHV-1 containing three
stop codons that should prevent LR protein expression leads to
a reduced ability of virus to replicate in the eye during acute
infection (48), lower levels of viral DNA in latently infected
TG, and a severe defect in virus reactivation after dexameth-
asone treatment of latently infected animals (49).
A complex pattern of alternative splicing in the LR tran-
script (LRT) has been described (27). LRT splicing varied
according to the source of LR RNA (cell lines or TG), the time
postinfection, and the type of RNA [poly(A) or poly(A)]
used for the experiments. The splicing pattern allows for dif-
ferent combinations between methionine-initiated ORFs and
between methionine-initiated and non-methionine-initiated
ORFs which may result in different protein isoforms.
Figure 1 summarizes major differences between BHV-5 and
BHV-1 in the LR region. Whereas both viruses contain ORF1
in frame 1 (66% amino acid identity), the structure of BHV-5
frame 2 departs from that of BHV-1. In BHV-1, frame 2
contains an ORF (LRORF2) which could encode a 181-amino-
FIG. 1. Comparison of the LR regions of BHV-5 and BHV-1. The LR nucleotide positions are given above (BHV-5) and below (BHV-1) the
central stippled box, and the relative nucleotide positions are in bold (1 to 3,000 bp). Restriction sites are XhoI (X), XbaI (Xb), and SphI (S). The
dots above the BHV-1 LRT represent the positions of splice donor signals (27). Methionine- and non-methionine-initiated ORFs are represented
by black and open boxes, respectively. Asterisks indicate the positions of in-frame stop codons. BHV-1 neuron-specific transcriptional regulatory
regions NSB and NSTA are represented by boxes between XhoI and SphI sites. The hatched box in the BHV-5 regulatory region represents deleted
sequences. The structure of BHV-5 frames 1 and 2 is discussed in the text and shown in detail below in Fig. 2A and B.
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acid protein and a downstream reading frame without an
initiating methionine. In BHV-5, frame 2 is interrupted four
times, resulting in reading frames a to d (Fig. 1), with reading
frame a being the only one to be methionine initiated. Reading
frame a, which is truncated at 51 amino acids, and reading
frame b are 82 and 75% identical to the corresponding regions
in BHV-1 ORF2, respectively, while reading frames c and d are
frameshifted. Interestingly, all splicing donor sites mapped in
FIG. 2. (A) Alignment of BHV-1 LRORF2 with translated BHV-5 genomic sequence using tfastx, indicating the homologous BHV-5 ORF in
frame 2 (boxed), stop codons (), frameshift to BHV-5 frame 3 (/), conserved substitutions (:), identities (|), and remaining open sequence in
BHV-5 frame 3 (). Total aligned sequence (182 amino acids) is 69% identical with BHV-1 LRORF2. (B) Alignment of BHV-1 LRORF1
with translated BHV-5 sequence using tfastx. Identities and substitutions are labeled as for panel A. Total aligned sequence (367 amino acids) is
66% identical with BHV-1 LRORF1. (C) Alignment of BHV-1 and BHV-5 LR regulatory sequences represented by the hatched box in Fig. 1, using
FASTA. In BHV-1, the underlined sequence 1 was specifically protected from exonuclease digestion by ganglionic nuclear factors (25); underlined
sequence 2 was protected from exonuclease digestion by neuroblastoma nuclear factors (11). Potential TATA and CAT boxes are shown in bold.
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the BHV-1 LR transcript fall downstream of the carboxy ter-
minus of frame b, suggesting that if BHV-5 proteins were made
from this region they would differ substantially from BHV-1
LR products. A detailed comparison of LRORF2 and LRORF1
amino acid sequences between the two viruses is shown in Fig.
2A and B.
The promoter which drives BHV-1 LR transcription is con-
tained near the 5	 terminus of the LR gene (53) and includes
two neuron-specific regulatory regions designated the neuron-
specific binding protein region and neuron-specific transcrip-
tion activator (NSB and NSTA, respectively) (Fig. 1) (11, 25).
While regions in the vicinity of the TATA box are conserved
between BHV-5 and BHV-1, nucleotide sequences 5	 of NSTA
are poorly conserved or lacking in BHV-5 (Fig. 2C). These
sequences were shown to be important for efficient enhancer
activity of the BHV-1 LR promoter in neuroblastoma cells and
for binding of nuclear factors (11). The NSB region is 72 bp in
length, specifically binds bovine ganglionic nuclear factors,
and is required for maximal BHV-1 LR promoter activity in
neuroblastoma cells (25). Almost 70% of the NSB region is
deleted in BHV-5, including a 20-bp region responsible for
binding to neuron-specific factors (25) (Fig. 2C) and a latency-
specific transcription start site (44).
In summary, the BHV-5 LR region differs substantially from
the BHV-1 LR region in both coding and transcriptionally
regulatory regions. Given the potential significance of this re-
gion in viral latency and/or host range and the differential
pathogenesis of these closely related viruses, it is likely that
these differences are of biological significance for aspects of
virus-neuron-host interactions.
Conclusions. Although BHV-5 and BHV-1 are closely re-
lated viruses, only BHV-5 causes CNS disease. The molecular
basis for the differential pathogenesis remains unknown but
probably arises from multiple genetic contributions. The com-
plete BHV-5 genome provides a framework from which com-
parisons between BHV-5 and BHV-1 pathogenesis may be
made. Strategies based on the construction of chimeric viruses
will certainly contribute to our overall understanding of patho-
gen-host interactions and the evolution of herpesvirus viru-
lence.
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